Gold prices edge higher; Fed indepedence fears spur safe haven buying
On Monday, Turnstone Biologics (NASDAQ:TSBX) experienced a change in stock rating as BofA Securities downgraded the company from Buy to Neutral. The price target was also significantly adjusted to $0.50 from the previous $10.00. The adjustment follows Turnstone's announcement of a major workforce reduction and strategic realignment towards its lead program, TIDAL-01.
Turnstone Biologics declared its intention to decrease its headcount by approximately 60% and realign resources to prioritize the development of TIDAL-01, a therapy aimed at treating challenging cancers such as colorectal cancer, head and neck cancer, and uveal melanoma.
This move is expected to extend the company's cash runway until the second quarter of 2026, compared to the previously anticipated third quarter of 2025. The restructuring is also anticipated to reduce the immediate need for additional funding before the release of significant data updates in the first half of 2025.
Concurrently with the restructuring announcement, Turnstone Biologics reported several changes in its executive leadership. This includes the retirement of the interim Chief Medical Officer, Michael Burgess, and the promotion of Saryah Azmat to Chief Operating Officer, along with other senior leadership transitions.
BofA Securities' analyst noted that while the restructuring and focus on the TIDAL-01 program appear to be pragmatic steps, it is prudent to adopt a wait-and-see strategy. The firm looks forward to observing more mature data in the coming year to better evaluate the company's long-term prospects. Consequently, the downgrade reflects a more cautious stance, with the new price target based on revised peak revenue projections and adjustments to operating expenses and share count.
In other recent news, Turnstone Biologics has seen a flurry of activity, including strategic organizational changes, trial updates, and financial reports. The biotech company announced a significant restructuring to prioritize its clinical program, TIDAL-01, in the development of treatments for solid tumors. The reorganization involved a workforce reduction of approximately 60% and leadership changes, aiming to extend the company's cash runway into the second quarter of 2026.
Turnstone Biologics also reported its first-quarter earnings for 2024, with a cash reserve of $78 million, sufficient to support operations into the latter half of 2025. In addition, the company revealed initial data from the ongoing STARLING trial of TIDAL-01. The trial results showed clinical benefits for two out of four patients with mismatch repair-proficient metastatic colorectal cancer.
Analyst firm Piper Sandler adjusted its price target for Turnstone Biologics to $3.75 from the previous $20.00, while maintaining an Overweight rating on the stock. The firm's decision is associated with Turnstone's strategic shift in research priorities and the inclusion of head and neck squamous cell carcinoma into their model.
Furthermore, Turnstone Biologics announced positive preliminary data from its Phase 1 STARLING trial evaluating TIDAL-01, a novel therapy for metastatic colorectal cancer. The trial reported an overall response rate of 25% and a disease control rate of 50% among the first four evaluable patients treated with TIDAL-01. The company plans to present a clinical update on TIDAL-01, expected to coincide with its second-quarter 2024 earnings report.
InvestingPro Insights
The recent downgrade of Turnstone Biologics (NASDAQ:TSBX) by BofA Securities aligns with several key metrics and insights from InvestingPro. The company's stock has been under significant pressure, with InvestingPro data showing a staggering 81.14% price decline over the past three months and an 84.85% drop over the last year. This downward trend is further emphasized by the fact that the stock is trading at just 8.03% of its 52-week high.
InvestingPro Tips highlight that Turnstone is "quickly burning through cash" and "not profitable over the last twelve months," which contextualizes the company's decision to reduce its workforce and focus on its lead program. The restructuring aims to extend the cash runway, addressing the concern of rapid cash burn.
Additionally, the InvestingPro Tip noting that the "RSI suggests the stock is in oversold territory" may provide some context for the current stock price, which stands at $0.46, significantly below the InvestingPro Fair Value of $0.63 and the analyst fair value target of $6.00. This discrepancy between current price and estimated fair values underscores the market's current pessimism towards Turnstone's prospects.
For investors seeking a more comprehensive analysis, InvestingPro offers 15 additional tips for Turnstone Biologics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.